A recent study suggests that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop conventional lifestyle programs.
Research printed in a major medical journal demonstrates that while obese people can lose about a fifth of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Users purchasing these medications need to be aware of the potential of fast rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to starting weight in about 18 months.
Weighing Approaches
The research, which examined 37 of studies involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with older methods.
The team emphasize that people who lose weight through diet and exercise typically have a slower creep back—around 100 grams monthly—post-intervention.
The Reason for the Quick Regain
Nutrition scientists propose the way of the jabs explains the accelerated weight return.
The injections mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations several times higher than normal could lead to the body to produce less of its own natural hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication means appetite is no longer kept in check, making binge eating a significant risk."
An Ongoing Disease?
The NHS recommend the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, due to the significant potential of weight regain, the therapy might need to be ongoing.
This view is supported by pharmaceutical companies, who say that the results "emphasize the long-term nature of excess weight," similar to managing diseases like hypertension.
User Experiences
Users who have stopped the jabs explain a intense return of appetite.
"It felt as if a switch activating and you're instantly extremely hungry," recalled a patient.
This challenge is worsened if individuals have not established lasting lifestyle or habit modifications during treatment.
Growing Use
Survey data show that millions of people in the UK have tried these injections in the past year, with desire being substantial.
- Use is more common among women compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Finally, clinicians emphasize that while the jabs are potent agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on ongoing behavioural changes.
